Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma

NCT06705725 is registered in ClinicalTrials.gov with Carbiogene Therapeutics Co. Ltd. as lead sponsor.

NCT NCT06705725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06705725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma
Lead sponsor
Carbiogene Therapeutics Co. Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 26, 2024
Completion date
February 22, 2028
Enrollment
38 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma